Liver-kidney pathophysiological interrelationships in liver diseases

Digestive and Liver Disease

Volumn 40, Issue 12, 2008, Pages 909-919

  Gentilini, P ^a   La Villa, G ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTIBIOTIC AGENT; CANRENONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; FUROSEMIDE; HUMAN ALBUMIN; HYDROCORTISONE; LOOP DIURETIC AGENT; LOSARTAN; MANNITOL; MIDODRINE; N(G) METHYLARGININE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; PLASMA SUBSTITUTE; RWJ 351647; SPIRONOLACTONE; TERLIPRESSIN; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VIRUS ANTIGEN;

ADRENAL INSUFFICIENCY; ASCITES; BACTERIAL PERITONITIS; BED REST; BILE ACID BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CELL INFILTRATION; CELL PROLIFERATION; CHOLESTASIS; CHRONIC LIVER DISEASE; COMPLEMENT ACTIVATION; DECOMPENSATED LIVER CIRRHOSIS; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HEART RATE; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; IMMUNE RESPONSE; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY ISCHEMIA; KIDNEY TUBULE ACIDOSIS; LIVER CIRRHOSIS; MACROPHAGE; MESANGIUM CELL; MONOCYTE; NONHUMAN; PARACENTESIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; SHORT SURVEY; SODIUM RESTRICTION; SODIUM RETENTION; TUBULAR DYSFUNCTION; VASCULAR RESISTANCE; VASOPRESSIN RELEASE;

ASCITES; HEPATORENAL SYNDROME; HUMANS; LIVER DISEASES; PORTAL VEIN;

EID: 55549144322     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.05.013     Document Type: Short Survey

References (103)

1. Arias I., Boyer J.L., Chisari F.V., Fausto N., Schachter D., and Shafritz D.A. The liver biology and pathobiology. fourth edition (2001), Lippincott & Wilkins, Philadelphia
2. Adachi A. Thermosensitive and osmoreceptive afferent fibers in the hepatic branch of the vagus nerve. J Auton Nerv Syst 10 (1984) 269-273
3. Nishida Y., Sugimoto I., Morita H., Murakami H., Hosomi H., and Bishop V.S. Suppression of renal sympathetic nerve activity during portal vein infusion of hypertonic saline. Am J Physiol 274 (1998) R97-103
4. Lang F., Tschernko E., Schulze E., Ottl I., Ritter M., Volkl H., et al. Hepatorenal reflex regulating kidney function. Hepatology 14 (1991) 590-594
5. + receptor of the Sprague-Dawley rat. Neurosci Lett 264 (1999) 65-68
6. DiBona G.F., and Sawin L.L. Hepatorenal baroreflex in cirrhotic rats. Am J Physiol 269 (1995) G29-G33
7. Anderson R.J., Cronin R.E., McDonald K.M., and Schrier R.W. Mechanisms of portal hypertension-induced alterations in renal hemodynamics, renal water excretion, and renin secretion. J Clin Invest 58 (1976) 964-970
8. Safirstein R., and Levitt M.F. A hepatorenal depressor reflex: a possible clue to the pathogenesis of the hepatorenal syndrome. Hepatology 14 (1991) 734-735
9. Murakami S., Ohnishi A., Matsuo A., Kawai B., Tada T., Kunihiro N., et al. Hepatic denervation ameliorates sodium and water retention in experimental cirrhosis in rats. Dig Dis Sci 42 (1997) 2292-2298
10. Stanley A.J., Redhead D.N., Bouchier I.A., and Hayes P.C. Acute effects of transjugular intrahepatic portosystemic stent-shunt (TIPSS) procedure on renal blood flow and cardiopulmonary hemodynamics in cirrhosis. Am J Gastroenterol 93 (1998) 2463-2468
11. Jalan R., Forrest E.H., Redhead D.N., Dillon J.F., and Hayes P.C. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man?. Gut 40 (1997) 664-670
12. Ellis A.J., and O'Grady J.G. Clinical disorders of renal function in acute liver failure. In: Arroyo V., Ginès P., and Rodès P. (Eds). Ascites and renal dysfunction in liver disease (2005), Blackwell Science, Oxford 63-78
13. Gentilini P., Laffi G., Buzzelli G., Stefani P., Scarpelli P., Paladini S., et al. Functional renal alterations in chronic liver diseases. Digestion 20 (1980) 73-78
14. Gentilini P., Laffi G., La Villa G., Romanelli R.G., Buzzelli G., Casini-Raggi V., et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol 92 (1997) 66-72
15. Oster J.R., and Perez G.O. Derangements of acid-base homeostasis in liver disease. In: Epstein M. (Ed). The kidney in liver disease. fourth edition (1996), Hanley & Belfus, Philadelphia 109-122
16. Ahya S.N., José Soler M., Levitsky J., and Batlle D. Acid-base and potassium disorders in liver disease. Semin Nephrol 26 (2006) 466-470
17. Krapf R., Seldin D.W., and Alpern R.J. Clinical syndromes of metabolic acidosis. In: Seldin D.W., and Giebisch G. (Eds). The kidney, physiology and pathophysiology. III edition (2000), Lippincott Williams and Wilkins, Philadelphia 2073-2130
18. Golding P.L. Renal tubular acidosis in chronic liver disease. Postgrad Med J 51 (1975) 550-556
19. Gentilini P., La Villa G., and Romanelli R.G. Renal impairment in chronic liver disease with and without cholestasis. In: Gentilini P., Arias I.M., Mc Intyre N., et al. (Eds). Cholestasis (1994), Elsevier Science B.V., Amsterdam 213-226
20. Alon U., Berant M., Mordechovitz D., and Better O.S. The effect of intrarenal infusion of bile on kidney function in the dog. Clin Sci (Lond) 62 (1982) 431-433
21. Eknoyan G. Glomerular abnormalities in liver disease. In: Epstein M. (Ed). The kidney in liver disease. fourth edition (1996), Hanley & Belfus Inc., Philadelphia 123-150
22. Johnson R.J., and Couser W.G. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 37 (1990) 663-676
23. Crawford D.H., Endre Z.H., Axelsen R.A., Lynch S.V., Balderson G.A., Strong R.W., et al. Universal occurrence of glomerular abnormalities in patients receiving liver transplants. Am J Kidney Dis 19 (1992) 339-344
24. Abramosky C., Dahms B., and Swinehart G. IgA-associated glomerular deposits in liver disease. Hum Pathol 16 (1985) 243-1246
25. Bene M.C., De Konvin J.D., Harault de Ligny B.H., Aymard B., Kessler M., and Faure G.C. IgA nephropathy and alcoholic liver cirrhosis. Am J Clin Pathol 89 (1988) 769-773
26. Lai K.N., and Lai F.M. Clinical features and the natural course of hepatitis B virus-related glomerulopathy in adults. Kidney Int Suppl 35 (1991) S40-S45
27. Johnson R.J., Gretch D.R., Yamabe H., Hart J., Bacchi C.E., Hartwell P., et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328 (1993) 465-470
28. Brunkhorst R., Kliem V., and Koch K.M. Recurrence of membranoproliferative glomerulonephritis after renal transplantation in a patient with chronic hepatitis C. Nephron 72 (1996) 465-467
29. Bosch J., D'Amico G., and Garcia-Pagan J.C. Portal hypertension and nonsurgical management. In: Schiff E.R., Sorrell M.F., and Maddrey W.C. (Eds). Schiff's diseases of the liver. tenth edition (2007), Lippincott Williams & Wilkins, Philadelphia 419-484
30. Pinzani M., Failli P., Ruocco C., Casini A., Milani S., Baldi E., et al. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest 90 (1992) 642-646
31. Kowalski H.J., and Abelmann W.H. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 32 (1953) 1025-1033
32. Arroyo V., and Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 38 (2003) S69-S89
33. Gentilini P., La Villa G., Laffi G., and Pinzani M. Hemodynamic derangement and cardiac dysfunction in cirrhosis. Ann Ital Med Int 19 (2004) 90-97
34. Garcia-Pagan J.C., Salmeron J.M., Feu F., Luca A., Gines P., Pizcueta P., et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 19 (1994) 1095-1099
35. Schrier R.W., Arroyo V., Bernardi M., Epstein M., Henriksen J.H., and Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8 (1988) 1151-1157
36. Lewis F.W., Adair O., and Rector Jr. W.G. Arterial vasodilation is not the cause of increased cardiac output in cirrhosis. Gastroenterology 102 (1992) 1024-1029
37. Bernardi M., Di Marco C., Trevisani F., De Collibus C., Fornale L., Baraldini M., et al. The hemodynamic status of preascitic cirrhosis: an evaluation under steady-state conditions and after postural change. Hepatology 16 (1992) 341-346
38. Laffi G., Barletta G., La Villa G., Del Bene R., Riccardi D., Ticali P., et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 113 (1997) 891-898
39. Gentilini P., Laffi G., Fantini F., di Donato M., Dabizzi R.P., La Villa G., et al. Systemic hemodynamics and renal function in cirrhotic patients during plasma volume expansion. Digestion 27 (1983) 138-145
40. Arroyo V., Gines P., Gerbes A.L., Dudley F.J., Gentilini P., Laffi G., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23 (1996) 164-176
41. Gentilini P., Casini-Raggi V., Di Fiore G., Romanelli R.G., Buzzelli G., Pinzani M., et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 30 (1999) 639-645
42. Martin P.Y., Gines P., and Schrier R.W. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 339 (1998) 533-541
43. Lopez-Talavera J.C., Levitzki A., Martinez M., Gazit A., Esteban R., and Guardia J. Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites. J Clin Invest 100 (1997) 664-670
44. Fernandez J., Escorsell A., Zabalza M., Felipe V., Navasa M., Mas A., et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 44 (2006) 1288-1295
45. De las Heras D., Fernandez J., Gines P., Cardenas A., Ortega R., Navasa M., et al. Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology 38 (2003) 452-459
46. Gentilini P., and Laffi G. Pathophysiology and treatment of ascites and the hepatorenal syndrome. Baillieres Clin Gastroenterol 6 (1992) 581-607
47. Epstein M., Schneider N., and Befeler B. Relationship of systemic and intrarenal hemodynamics in cirrhosis. J Lab Clin Med 89 (1977) 1175-1187
48. Epstein M., Loutzenhiser R., Friedland E., Aceto R.M., Camargo M.J., and Atlas S.A. Relationship of increased plasma atrial natriuretic factor and renal sodium handling during immersion-induced central hypervolemia in normal humans. J Clin Invest 79 (1987) 738-745
49. Laffi G., La Villa G., and Gentilini P. Pathogenesis and management of the hepatorenal syndrome. Semin Liver Dis 14 (1994) 71-81
50. Epstein M., Berk D.P., Hollenberg N.K., Adams D.F., Chalmers T.C., Abrams H.L., et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 49 (1970) 175-185
51. Koppel M.H., Coburn J.N., Mims M.M., Goldtein H., Boyle H., and Rubini M.E. Trasplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Eng J Med 280 (1969) 1367-1371
52. Schrier R.W., Gross P., Gheorghiade M., Berl T., Verbalis J.G., Czerwiec F.S., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355 (2006) 2099-2112
53. Thuluvath P.J., Maheshwari A., Wong F., Yoo H.W., Schrier R.W., Parikh C., et al. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. Aliment Pharmacol Ther 24 (2006) 973-982
54. Gonwa T.A., Klintmalm G.B., Levy M., Jennings L.S., Goldstein R.M., and Husberg B.S. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 59 (1995) 361-365
55. Gentilini P, Hepatorenal syndrome: differential diagnosis and therapy. In: Schmidt R, Gerok W, Bianchi L, Maier KP, editors. Extrahepatic manifestation in liver diseases. Falk Symposium 69. Kluwer Acad. Publ.; 1993, Dordrecht, p. 193-212.
56. Fernandez-Seara J., Prieto J., Quiroga J., Zozaya J.M., Cobos M.A., Rodriguez-Eire J.L., et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 97 (1989) 1304-1312
57. Hernandez-Guerra M., Lopez E., Bellot P., Piera C., Turnes J., Abraldes J.G., et al. Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. Hepatology 43 (2006) 27-33
58. Maroto A., Gines P., Arroyo V., Gines A., Salo J., Claria J., et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 17 (1993) 788-793
59. Kew M.C., Brunt P.W., Varma R.R., Hourigan K.J., Williams H.S., and Sherlock S. Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet 2 (1971) 504-510
60. Wilkinson S.P., Smith I.K., Clarke M., Arroyo V., Richardson J., Moodie H., et al. Intrarenal distribution of plasma flow in cirrhosis as measured by transit renography: relationship with plasma renin activity, and sodium and water excretion. Clin Sci 52 (1977) 469-475
61. Lagi A., La Villa G., Barletta G., Cencetti S., Bacalli S., Cipriani M., et al. Cerebral autoregulation in patients with cirrhosis and ascites. A transcranial Doppler study. J Hepatol 27 (1997) 114-120
62. Guevara M., Bru C., Gines P., Fernandez-Esparrach G., Sort P., Bataller R., et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 28 (1998) 39-44
63. Grose R.D., Nolan J., Dillon J.F., Errington M., Hannan W.J., Bouchier I.A., et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol 22 (1995) 326-332
64. Bernardi M., Rubboli A., Trevisani F., Cancellieri C., Ligabue A., Baraldini M., et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J Hepatol 12 (1991) 207-216
65. Trevisani F., Sica G., Mainqua P., Santese G., De Notariis S., Caraceni P., et al. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology 30 (1999) 1387-1392
66. Gentilini P., Vizzutti F., Gentilini A., Zipoli M., Foschi M., and Romanelli R.G. Update on ascites and hepatorenal syndrome. Dig Liver Dis 34 (2002) 592-605
67. Associazione italiana per lo Studio del fegato.(AISF). Diagnosi e trattamento del paziente ascitico. Linee Guida. A cura della Commissione "Ascite" dell'A.I.S.F.
68. Gines P., Arroyo V., Quintero E., Planas R., Bory F., Cabrera J., et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 93 (1987) 234-241
69. Sort P., Navasa M., Arroyo V., Aldeguer X., Planas R., Ruiz-del-Arbol L., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341 (1999) 403-409
70. Gines A., Escorsell A., Gines P., Salo J., Jimenez W., Inglada L., et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 105 (1993) 229-236
71. Uriz J., Gines P., Cardenas A., Sort P., Jimenez W., Salmeron J.M., et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33 (2000) 43-48
72. Angeli P., Volpin R., Gerunda G., Craighero R., Roner P., Merenda R., et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29 (1999) 1690-1697
73. Gentilini P., Romanelli R.G., La Villa G., Maggiore Q., Pesciullesi E., Cappelli G., et al. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 104 (1993) 588-594
74. Therapondos G., Hol L., Benjaminov F., and Wong F. The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis. Hepatology 44 (2006) 640-649
75. Skorecki K.L., Leung W.M., Campbell P., Warner L.C., Wong P.Y., Bull S., et al. Role of atrial natriuretic peptide in the natriuretic response to central volume expansion induced by head-out water immersion in sodium-retaining cirrhotic subjects. Am J Med 85 (1988) 375-382
76. Bernardi M., Fornale L., Di Marco C., Trevisani F., Baraldini M., Gasbarrini A., et al. Hyperdynamic circulation of advanced cirrhosis: a re-appraisal based on posture-induced changes in hemodynamics. J Hepatol 22 (1995) 309-318
77. Wong F., Sniderman K., Liu P., Allidina Y., Sherman M., and Blendis L. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 122 (1995) 816-822
78. Pockros P.J., and Reynolds T.B. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology 90 (1986) 1827-1833
79. Gines P., Tito L., Arroyo V., Planas R., Panes J., Viver J., et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94 (1988) 1493-1502
80. Morgan T.R., Imada T., Hollister A.S., and Inagami T. Plasma human atrial natriuretic factor in cirrhosis and ascites with and without functional renal failure. Gastroenterology 95 (1988) 1641-1647
81. Epstein M. Renal effects of head-out water immersion in humans: a 15-year update. Physiol Rev 72 (1992) 563-621
82. La Villa G., Romanelli R.G., Casini Raggi V., Tosti-Guerra C., De Feo M.L., Marra F., et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology 16 (1992) 156-161
83. La Villa G., Asbe rt M., Jimenez W., Gines P., Claria J., Lopez C., et al. Natriuretic hormone activity in the urine of cirrhotic patients. Hepatology 12 (1990) 467-475
84. La Villa G., Riccardi D., Lazzeri C., Casini Raggi V., Dello Sbarba A., Tosti Guerra C., et al. Blunted natriuretic response to low-dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention. Hepatology 22 (1995) 1745-1750
85. Guevara M., Gines P., Jimenez W., Sort P., Fernandez-Esparrach G., Escorsell A., et al. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 114 (1998) 336-343
86. Elhawary A.M., and Pang C.C. Renal vascular and tubular actions of calcitonin gene-related peptide: effect of NG-nitro-l-arginine methyl ester. J Pharmacol Exp Ther 273 (1995) 56-63
87. Zipser R.D., Radvan G.H., Kronborg I.J., Duke R., and Little T.E. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 84 (1983) 697-703
88. Laffi G., La Villa G., Pinzani M., Ciabattoni G., Patrignani P., Mannelli M., et al. Altered renal and platelet arachidonic acid metabolism in cirrhosis. Gastroenterology 90 (1986) 274-282
89. Laffi G., La Villa G., and Pinzani M. Lipid-derived autacoids and renal function in liver cirrhosis. In: Epstein M. (Ed). The kidney in liver disease (1988), Hanley & Belfus, Philadelphia 307-337
90. Zipser R.D., Kronborg I., Rector W., Reynolds T., and Daskalopoulos G. Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome. Gastroenterology 87 (1984) 1228-1232
91. Gentilini P., Laffi G., Meacci E., La Villa G., Cominelli F., Pinzani M., et al. Effects of OKY 046, a thromboxane-synthase inhibitor, on renal function in nonazotemic cirrhotic patients with ascites. Gastroenterology 94 (1988) 1470-1477
92. Laffi G., Marra F., Carloni V., Azzena G., De Feo M.L., Pinzani M., et al. Thromboxane-receptor blockade increases water diuresis in cirrhotic patients with ascites. Gastroenterology 103 (1992) 1017-1021
93. Perez-Ayuso R.M., Arroyo V., Camps J., Rimola A., Costa J., Gaya J., et al. Renal kallikrein excretion in cirrhotics with ascites: relationship to renal hemodynamics. Hepatology 4 (1984) 247-252
94. Chan L., Chittinandana A., Shapiro J.I., Shanley P.F., and Schrier R.W. Effect of an endothelin-receptor antagonist on ischemic acute renal failure. Am J Physiol 266 1 Pt 2 (1994) F138
95. Rabelink T.J., Kaasjager K.A., Boer P., Stroes E.G., Braam B., and Koomans H.A. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int 46 (1994) 376-381
96. Moore K., Wendon J., Frazer M., Karani J., Williams R., and Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 327 (1992) 1774-1778
97. Guevara M., Gines P., Bandi J.C., Gilabert R., Sort P., Jimenez W., et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 28 (1998) 416-422
98. Vallance P., and Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide?. Lancet 337 (1991) 776-778
99. Albillos A., Rossi I., Cacho G., Martinez M.V., Millan I., Abreu L., et al. Enhanced endothelium-dependent vasodilation in patients with cirrhosis. Am J Physiol 268 March (3 Pt 1) (1995) G459-G464
100. Pizcueta P., Pique J.M., Fernandez M., Bosch J., Rodes J., Whittle B.J., et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 103 (1992) 1909-1915
101. La Villa G., Barletta G., Pantaleo P., Del Bene R., Vizzutti F., Vecchiarino S., et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 34 (2001) 19-27
102. Gupta T.K., Toruner M., Chung M.K., and Groszmann R.J. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 28 (1998) 926-931
103. Guarner C., Runyon B.A., Young S., Heck M., and Sheikh M.Y. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 26 (1997) 1372-1378